Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 45

1.

Spherical nucleic acids.

Cutler JI, Auyeung E, Mirkin CA.

J Am Chem Soc. 2012 Jan 25;134(3):1376-91. doi: 10.1021/ja209351u. Epub 2012 Jan 9.

PMID:
22229439
2.

Delivery of siRNA and other macromolecules into skin and cells using a peptide enhancer.

Hsu T, Mitragotri S.

Proc Natl Acad Sci U S A. 2011 Sep 20;108(38):15816-21. doi: 10.1073/pnas.1016152108. Epub 2011 Sep 8.

3.

Polyvalent nucleic acid nanostructures.

Cutler JI, Zhang K, Zheng D, Auyeung E, Prigodich AE, Mirkin CA.

J Am Chem Soc. 2011 Jun 22;133(24):9254-7. doi: 10.1021/ja203375n. Epub 2011 Jun 1.

4.

Therapeutic effects on atopic dermatitis by anti-RelA short interfering RNA combined with functional peptides Tat and AT1002.

Uchida T, Kanazawa T, Kawai M, Takashima Y, Okada H.

J Pharmacol Exp Ther. 2011 Aug;338(2):443-50. doi: 10.1124/jpet.111.180042. Epub 2011 Apr 29.

5.

A benefit-risk assessment of erlotinib in non-small-cell lung cancer and pancreatic cancer.

Mountzios G, Syrigos KN.

Drug Saf. 2011 Mar 1;34(3):175-86. doi: 10.2165/11586540-000000000-00000. Review.

PMID:
21332242
6.

Potent engineered PLGA nanoparticles by virtue of exceptionally high chemotherapeutic loadings.

Enlow EM, Luft JC, Napier ME, DeSimone JM.

Nano Lett. 2011 Feb 9;11(2):808-13. doi: 10.1021/nl104117p. Epub 2011 Jan 25.

7.

Development of skin-humanized mouse models of pachyonychia congenita.

GarcĂ­a M, Larcher F, Hickerson RP, Baselga E, Leachman SA, Kaspar RL, Del Rio M.

J Invest Dermatol. 2011 May;131(5):1053-60. doi: 10.1038/jid.2010.353. Epub 2010 Dec 9.

8.

MITF-siRNA formulation is a safe and effective therapy for human melasma.

Yi X, Zhao G, Zhang H, Guan D, Meng R, Zhang Y, Yang Q, Jia H, Dou K, Liu C, Que F, Yin JQ.

Mol Ther. 2011 Feb;19(2):362-71. doi: 10.1038/mt.2010.263. Epub 2010 Nov 30.

9.

Scavenger receptors mediate cellular uptake of polyvalent oligonucleotide-functionalized gold nanoparticles.

Patel PC, Giljohann DA, Daniel WL, Zheng D, Prigodich AE, Mirkin CA.

Bioconjug Chem. 2010 Dec 15;21(12):2250-6. doi: 10.1021/bc1002423. Epub 2010 Nov 11.

10.

Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy.

Kolishetti N, Dhar S, Valencia PM, Lin LQ, Karnik R, Lippard SJ, Langer R, Farokhzad OC.

Proc Natl Acad Sci U S A. 2010 Oct 19;107(42):17939-44. doi: 10.1073/pnas.1011368107. Epub 2010 Oct 4.

11.

Cellular response of polyvalent oligonucleotide-gold nanoparticle conjugates.

Massich MD, Giljohann DA, Schmucker AL, Patel PC, Mirkin CA.

ACS Nano. 2010 Oct 26;4(10):5641-6. doi: 10.1021/nn102228s.

12.

Inhibition of mutated, activated BRAF in metastatic melanoma.

Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB.

N Engl J Med. 2010 Aug 26;363(9):809-19. doi: 10.1056/NEJMoa1002011.

13.

Nonviral transfection strategies for keratinocytes, fibroblasts, and endothelial progenitor cells for ex vivo gene transfer to skin wounds.

Dickens S, Van den Berge S, Hendrickx B, Verdonck K, Luttun A, Vranckx JJ.

Tissue Eng Part C Methods. 2010 Dec;16(6):1601-8. doi: 10.1089/ten.TEC.2009.0648. Epub 2010 Aug 28.

PMID:
20666605
14.

Gold nanoparticles for biology and medicine.

Giljohann DA, Seferos DS, Daniel WL, Massich MD, Patel PC, Mirkin CA.

Angew Chem Int Ed Engl. 2010 Apr 26;49(19):3280-94. doi: 10.1002/anie.200904359. Review.

15.

Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles.

Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, Alabi CA, Yen Y, Heidel JD, Ribas A.

Nature. 2010 Apr 15;464(7291):1067-70. doi: 10.1038/nature08956. Epub 2010 Mar 21.

16.

Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.

Griffiths CE, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, Guzzo C, Xia Y, Zhou B, Li S, Dooley LT, Goldstein NH, Menter A; ACCEPT Study Group.

N Engl J Med. 2010 Jan 14;362(2):118-28. doi: 10.1056/NEJMoa0810652.

17.

Cutaneous short-interfering RNA therapy.

Geusens B, Sanders N, Prow T, Van Gele M, Lambert J.

Expert Opin Drug Deliv. 2009 Dec;6(12):1333-49. doi: 10.1517/17425240903304032. Review.

PMID:
19941411
18.

First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder.

Leachman SA, Hickerson RP, Schwartz ME, Bullough EE, Hutcherson SL, Boucher KM, Hansen CD, Eliason MJ, Srivatsa GS, Kornbrust DJ, Smith FJ, McLean WI, Milstone LM, Kaspar RL.

Mol Ther. 2010 Feb;18(2):442-6. doi: 10.1038/mt.2009.273. Epub 2009 Nov 24.

19.

Regulating immune response using polyvalent nucleic acid-gold nanoparticle conjugates.

Massich MD, Giljohann DA, Seferos DS, Ludlow LE, Horvath CM, Mirkin CA.

Mol Pharm. 2009 Nov-Dec;6(6):1934-40. doi: 10.1021/mp900172m.

20.

Inhibition of the hedgehog pathway in advanced basal-cell carcinoma.

Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Mackey HM, Lum BL, Darbonne WC, Marsters JC Jr, de Sauvage FJ, Low JA.

N Engl J Med. 2009 Sep 17;361(12):1164-72. doi: 10.1056/NEJMoa0905360. Epub 2009 Sep 2.

Supplemental Content

Support Center